Dalcetrapib

N/A

Report date: 2026/05/17 20:00:15
NME

Base Information

Drug NameDalcetrapib
Drug Alias Namedalcetrapib达塞曲匹dalcetrapibum道西曲匹达彻普 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHDL-cholesterol stimulantsCholesteryl ester transfer protein inhibitors
TargetsHDL-cholesterolCholesteryl ester transfer protein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)DyslipidemiasHyperlipoproteinemia Type II +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPending
Originator CompaniesDalcor
China Registration ClassN/A

Develop Information

Active CompaniesDalcor Pharmaceuticals
Inactive CompaniesF. Hoffmann-La Roche LtdJapan Tobacco IncAkros Pharma Inc
Active IndicationsAcute Coronary Syndrome
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)DyslipidemiasHyperlipoproteinemia Type II +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG